Ryoncil: ODAC/FDA Meeting Discussion, page-1980

What an emotional roller coaster this last week has been as the MSB share price surged towards $5 and then tanked on the FDA briefing note and ill-informed AFR reporting fiasco, and finally culminating in the successful ODAC meeting result.

I’ve never listened to anything quite like the ODAC meeting overnight and it was enthralling and draining as much as it made me swing between hopefulness, confidence, pride, worry, anger, frustration, and exasperation. It was a truly company making performance by Silviu, Grossman and Geraldine, and backed up by invaluable key note presenters and moving public submissions by families affected by GVHD.

Despite the MSB team’s best efforts, I was actually preparing for and expecting the worst during the 10 minute voting period and was seriously questioning my reasoning for being all-in with MSB and perhaps not taking the opportunity to sell half yesterday to hedge my bet. What a relieving result it was personally but also for paediatric GVHD patients and their families.

Whilst imminent FDA approval is not certain but likely, success would result in an incredible breakthrough and validation for this first-mover Australian stem cell company. The resultant credibility and ‘seat at the table’ with the big boys in the USA and FDA will be the impetus for further relationships, products and success going forward. Fingers crossed.

And to the down rampers and blatant trolls, I will not say what I would like to as this will only bring me down towards your level. I’m not even going to mention names as you know exactly who you are.

What a great Friday. Good luck to all.